

# High-Sensitivity Troponin and the Diagnosis of NSTEMI in Hospitalized Medical Patients

**Gidi Stein, Danny Alon, Roman Korenfeld,  
Shmuel Fuchs**

Department of Internal Medicine "B", Beilinson Hospital,  
Rabin Medical Center

IHS Annual Meeting, April 22-23, 2013, Jerusalem Israel

# Conflict of interest

NONE

# Background

- The 3<sup>rd</sup> universal definition of MI
  - “...detection of a rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit and with a strong pre-test likelihood”
- ACCF 2012 expert consensus document
  - “...an elevated troponin is a finding that represents the likely occurrence of myocardial necrosis and does not in and of itself provide any indication of the etiology”

# Background

- Troponin levels were obtained in 25% of ER all-comers (*McFalls et al. Am J Med. 2011*) and its utilization is steadily growing at 6.9% annually
- Several studies examine relative and absolute changes in hsTn levels in the distinction of ischemic vs. non-ischemic conditions
  - Diff > 0.009 ug/l - *Mueller et al. Clinical Chemistry, 2012*
  - Diff > 30% - *Agewall et al. EHJ, 2011*
  - Diff > 50% (20% if b/l is  $\hat{u}$ ) - *Thygesen et al. EHJ, 2012*

# Background

- Since 2010, high-sensitivity troponin assays are being used in Rabin Medical Center
- Data is lacking on the prevalence and kinetics of elevated high-sensitivity troponin levels in hospitalized complex patients

# Study outline

- All patients hospitalized to 8 medical wards in Rabin Medical Center, Israel throughout 2011
- 18,830 admissions of 13,029 patients were included in the study
- 5,696 admissions of 4,615 patients with at least one high-sensitivity Troponin (hsTn) measurement **(30%)**
- 10,021 hsTn measurements were included

# Baseline Characteristics

---

Age (average $\pm$ stdev)	71.5 $\pm$ 15
Male gender (%)	53.5
<i>Acute diagnosis (%)</i>	
Non specific chest pain	24.1
Acute coronary syndrome	2.1
<b>Myocardial infarction</b>	<b>4</b>
Heart failure	23
Anemia	21.9
COPD exacerbation	17.2
Acute renal failure	6.3
Pulmonary emboli	2
Sepsis	2

---

# Baseline Characteristics

---


## *Patient Comorbidities (%)*

Ischemic heart disease	41.7
Heart failure	24.3
Post CVA	14.1
Diabetes	35.7
Chronic renal failure	19.4
Atrial Fibrillation	25.2
COPD	16.9
Malignancy	13.7


---




# HsTn Measurements per Admission





# HsTn levels Distribution




# Absolute and Relative Change by hsTn Levels





# HsTn levels & % Change by Age & Renal Function



# HsTn Levels and Kinetics per Acute Dx




# Optimization for hsTn Levels and %-Change Cutoffs





- %-change does **not** contribute to precision
- HsTn threshold of 0.1 ug/l includes **60%** of ACS/MI and excludes **88%** of non-ACS/MI admissions

# HsTn $\geq$ 0.1 ug/l



# HsTn and 30-day Mortality





# Multivariate Analysis for 30-day Mortality

Parameter	OR (95% CI)	p
Age	1.03 (1.02, 1.04)	<0.0001
Creatinin	1.17 (1.1, 1.26)	<0.0001
Chest Pain	0.18 (0.1, 0.32)	<0.0001
Sepsis	11.17 (7.27, 17.17)	<0.0001
ARF	1.66 (1.18, 2.33)	0.004
MI/ACS	0.46 (0.27, 0.79)	0.005
<b>hsTn&gt;0.013</b>	<b>4.58 (2.8, 7.49)</b>	<b>&lt;0.0001</b>

# Conclusions I

- Elevated hsTn as well as its dynamic changes are common among hospitalized patients in Internal Medicine wards across multiple medical conditions
- Age and chronic renal failure are associated with elevated hsTn levels
- In 94% of the patients who had elevated hsTn the cause was not ACS/MI

# Conclusions II

- High max hsTn levels but **not** magnitude of dynamic changes were more frequent among patients with ACS
- HsTn > 99% percentile is an independent predictor for early mortality
- These results underline the complexity of the utilization of hsTn in diagnosis of NSTEMI in medical patients with atypical symptoms